RCUS (Arcus Biosciences) Tariff Resilience Score: 7/10 (As of Jun. 29, 2026)


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $31.08
GF Value $13.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences Tariff Resilience Score?

Arcus Biosciences RCUS +0.26% 46 Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.76 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,375 Biotechnology companies, Arcus Biosciences ranks better than 90.4% on this metric.

Arcus Biosciences has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Arcus Biosciences has RCUS, a biotech firm, has limited direct tariff exposure. Its focus on drug development and partnerships in the U.S. and Europe provides some insulation, though tariffs on imported research materials could have minor impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Arcus Biosciences might have Highly Resilient.

Arcus Biosciences  (NYSE:RCUS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Arcus Biosciences Tariff Resilience Score Related Terms

RCUS vs NAMS, CRNX, CPRX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Arcus Biosciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcus Biosciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's Tariff Resilience Score falls into.


RCUS
46GF Score
Arcus Biosciences Inc RCUS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Arcus Biosciences (RCUS) has a Tariff Resilience Score of 7 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Arcus Biosciences ranks #132 out of 1375 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Arcus Biosciences' Tariff Resilience Score too high?
Arcus Biosciences' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Arcus Biosciences' value of 7 is 75% above this industry median. Based on the distribution chart, Arcus Biosciences ranks #132 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' Tariff Resilience Score compare to NAMS and CRNX?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #132 out of 1375 companies for Tariff Resilience Score. This places Arcus Biosciences in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Arcus Biosciences' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcus Biosciences's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcus Biosciences's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.76, compared to a current price of $31.08 — trading 125.9% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $31.08 is trading 125.9% above its estimated GF Value™ of $13.76. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • Tariff Resilience Score: 7
  • GF Value™: $13.76 vs. price of $31.08 (125.9% above fair value)
  • GF Score™: 46/100 with 6 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1375)

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.08
Price
$13.76
GF Value